David Kipgen
Western Infirmary
16 Papers
12 Citations
David Kipgen is an academic researcher from Western Infirmary. The author has contributed to research in topics: Renal biopsy & Medicine. The author has an hindex of 6, co-authored 11 publications.
Chat about Author
Papers
The MEST score provides earlier risk prediction in lgA nephropathy
Sean J. Barbour,Sean J. Barbour,Gabriela Espino-Hernandez,Heather N. Reich,Rosanna Coppo,Ian S.D. Roberts,John Feehally,Andrew M. Herzenberg,Daniel C. Cattran,Nuket Bavbek,Terry Cook,Stéphan Troyanov,C. Alpers,Alessandro Amore,Jonathan Barratt,F. Berthoux,S. Bonsib,Jan A. Bruijn,V. D’Agati,Giuseppe D'Amico,Steven N. Emancipator,F. Emmal,Franco Ferrario,Fernando C. Fervenza,Sandrine Florquin,Agnes B. Fogo,Colin C. Geddes,Hermann Josef Groene,Mark Haas,Prue Hill,Ronald J. Hogg,S. Hsu,Tracy E. Hunley,Michelle Hladunewich,Caroline E. Jennette,Kensuke Joh,Bruce A. Julian,Tetsuya Kawamura,F. Lai,C. Leung,L. Li,P. Li,Z. Liu,Alfonso Eirin Massat,Bruce Mackinnon,Sergio Mezzano,Federico Schena,Yasuhiko Tomino,Patrick D. Walker,H. Wang,Jan J. Weening,N Yoshikawa,Hong Zhang,R. Coppo,Dan Cattran,H.T. Cook,J. Feehally,I. Roberts,V. Tesar,Dita Maixnerova,Sigrid Lundberg,Loreto Gesualdo,Francesco Emma,L. Fuiano,Giulietta Beltrame,Cristiana Rollino,Rc,Roberta Camilla,Licia Peruzzi,Manuel Praga,Sandro Feriozzi,Rosaria Polci,G. Segoloni,Loredana Colla,Antonello Pani,A. Angioi,L. Piras,Jf,Giovanni Cancarini,Sara Ravera,Magdalena Durlik,Elisabetta Moggia,J. Ballarin,S. Di Giulio,F. Pugliese,I. Serriello,Yasar Caliskan,Mehmet Sukru Sever,Isin Kilicaslan,Francesco Locatelli,L. Del Vecchio,Jack F.M. Wetzels,H. Peters,Ulla Berg,F. Carvalho,A.C. da Costa Ferreira,Milena Maggio,A. Wiecek,M. Ots-Rosenberg,Riccardo Magistroni,Rezan Topaloglu,Yelda Bilginer,Marco D'Amico,Maria Stangou,F. Giacchino,Dimitris Goumenos,Pantelitsa Kalliakmani,Miltiadis Gerolymos,Krešimir Galešić,Kostas C. Siamopoulos,Olga Balafa,Marco Galliani,Piero Stratta,Marco Quaglia,Roberto Bergia,Raffaella Cravero,Maurizio Salvadori,L. Cirami,Bengt Fellström,H. Kloster Smerud,T. Stellato,Jesús Egido,C. Martin,J. Floege,Frank Eitner,Antonio Lupo,Patrizia Bernich,P. Menè,M. Morosetti,C. van Kooten,Ton J. Rabelink,M. Reinders,J.M. Boria Grinyo,Stefano Cusinato,Luisa Benozzi,Silvana Savoldi,C. Licata,Małgorzata Mizerska-Wasiak,G. Martina,A. Messuerotti,A. Dal Canton,Ciro Esposito,C. Migotto,G. Triolo,Filippo Mariano,Claudio Pozzi,R. Boero,Shubha Bellur,Gianna Mazzucco,Costantinos Giannakakis,Eva Honsova,B. Sundelin,A.M. Di Palma,E. Gutiérrez,Anna Maria Asunis,Regina Tardanico,Agnieszka Perkowska-Ptasińska,J. Arce Terroba,M. Fortunato,Aphroditi Pantzaki,Yasemin Ozluk,Eric J. Steenbergen,Magnus Söderberg,Z. Riispere,L. Furci,Diclehan Orhan,David Kipgen,Donatella Casartelli,D. Galesic Ljubanovic,Hariklia Gakiopoulou,E. Bertoni,P. Cannata Ortiz,Henryk Karkoszka,Hermann-Josef Groene,A. Stoppacciaro,Ingeborg M. Bajema,X. Fulladosa Oliveras,J. Maldyk,E. Ioachim +178 more
TL;DR: Combining the MEST score with cross-sectional clinical data at biopsy provides earlier risk prediction in IgAN than current best methods, which requires clinical data over 2 years of follow-up.
250
Reproducibility of the Oxford classification of immunoglobulin A nephropathy, impact of biopsy scoring on treatment allocation and clinical relevance of disagreements: evidence from the VALidation of IGA study cohort.
Shubha Bellur,Ian S.D. Roberts,Stéphan Troyanov,Virginie Royal,Rosanna Coppo,H. Terence Cook,Daniel C. Cattran,Yolanda Arce Terroba,Anna Maria Asunis,Ingeborg M. Bajema,Elisabetta Bertoni,Jan A. Bruijn,Pablo Cannata-Ortiz,Donatella Casartelli,Anna Maria Di Palma,Franco Ferrario,Mirella Fortunato,L. Furci,Hariklia Gakiopoulou,Danica Galešić Ljubanović,Konstantinos Giannakakis,M. Gomà,Hermann Josef Gröne,Eduardo Gutiérrez,S. Asma Haider,Eva Honsova,Elli Ioachim,Henryk Karkoszka,David Kipgen,Jagoda Maldyk,Gianna Mazzucco,Diclehan Orhan,Yasemin Ozluk,Afroditi Pantzaki,Agnieszka Perkowska-Ptasińska,Zivili Riispere,Magnus Söderberg,Eric J. Steenbergen,Antonella Stoppacciaro,Birgitta Sundelin Von Feilitzen,Regina Tardanico +40 more
TL;DR: Since the decision to offer immunosuppressive therapy in this cohort was intimately associated with the MEST-C score, this study indicates a need for more detailed guidance for pathologists in the scoring of IgAN biopsies.
57
A rare cause of nephrotic syndrome in autosomal-dominant polycystic kidney disease
TL;DR: This is the first reported case of nephrotic syndrome due to lupus nephritis in a patient with autosomal dominant polycystic kidney disease (ADPKD) and underlines the importance of renal biopsy in patients with ADPKD and nephrotsic range proteinuria.
9
Erratum to: Risk factors for progression in children and young adults with IgA nephropathy: an analysis of 261 cases from the VALIGA European cohort (Pediatr Nephrol, 10.1007/s00467-016-3469-3)
R. Coppo,Danilo Lofaro,Roberta Camilla,Shubha Bellur,Dan Cattran,H.T. Cook,Ian Roberts,Licia Peruzzi,Alessandro Amore,Francesco Emma,L. Fuiano,Ulla Berg,Rezan Topaloglu,Yelda Bilginer,Loreto Gesualdo,Rosaria Polci,Małgorzata Mizerska-Wasiak,Yasar Caliskan,Sigrid Lundberg,Giovanni Cancarini,Colin C. Geddes,Jack F.M. Wetzels,Andrzej Wiecek,Magdalena Durlik,Stefano Cusinato,Cristiana Rollino,Milena Maggio,Manuel Praga,H. K. Smerud,V. Tesar,Dita Maixnerova,Jonathan Barratt,Teresa Papalia,Renzo Bonofiglio,Gianna Mazzucco,Costantinos Giannakakis,Magnus Söderberg,Diclehan Orhan,A.M. Di Palma,Jagoda Maldyk,Yasemin Ozluk,B. Sudelin,Regina Tardanico,David Kipgen,Eric J. Steenbergen,Henryk Karkoszka,Agnieszka Perkowska-Ptasińska,Franco Ferrario,E. Gutiérrez,Eva Honsova +49 more
TL;DR: Rosanna Coppo & Danilo Lofaro & Roberta R. Roberts & Licia Peruzzi & Alessandro Amore & Francesco Emma & Laura Fuiano & Ulla Berg & Rezan Topaloglu & Yelda Bilginer & Loreto Gesualdo & Rosaria Polci & Malgorzata Mizerska-Wasiak & Yasar Caliskan.
Early focal segmental glomerulosclerosis as a cause of renal allograft primary nonfunction.
TL;DR: This case highlights FSGS as a potentially aggressive process that, once active in the allograft, may prove refractory to targeted treatment and should be considered for patients deemed to be at high risk of recurrent disease.